SHORT-TERM EFFICACY AND SAFETY OF INTRAVITREAL RANIBIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION

Abstract

Short-term results of intravitreal ranibizumab for myopic CNV are encouraging. Further prospective long-term studies are necessary to evaluate safety and efficacy of intravitreal ranibizumab in the treatment of myopic CNV.